It is the only PAC dedicated to the interests of the rheumatology profession. RheumPAC was created in 2007 with the mission of educating, electing, and supporting federal lawmakers who understand and can positively address the issues that impact rheumatology care providers and their patients.
The ACR has long urged Congress to work towards long-term, sustainable reforms to Medicare physician reimbursement and applauds the introduction of the Medicare Patient Access and Practice Stabilization Act of 2025. It is critical to mitigate current cuts and work towards a long-term, sustainable solution to Medicare physician payment.
Cuts to Medicaid would be catastrophic for our nation’s most vulnerable populations, including low-income individuals and families, pregnant people, elderly adults, and individuals with disabilities, all populations where at least one in four adults are living with rheumatic disease.
Reinstate federal funding for programs engaged in vital research to combat rheumatic diseases, both at the NIH and at the Department of Defense through the Congressionally Directed Medical Research Program (CDMRP).
Support expansion of the rheumatology workforce by adequately funding Graduate Medical Education and permanently repealing the cap on Medicare funded training positions.
Ensure long-term, viable patient access to telehealth services by resolving inter-state licensing issues and preserving reimbursement parity for virtual visits.
Increase transparency required for pharmacy benefit manager (PBM) operations and drug pricing mechanisms, including reporting requirements for rebates and drug price increases.
Learn more about what the ACR is doing to protect and promote rheumatology.
Click here to find answers to the most commonly asked questions about RheumPAC and its role in the ACR's advocacy efforts.
Contribute to RheumPAC today and invest in the future of rheumatology! Every dollar raised goes directly towards supporting members of Congress who are champions of rheumatology care providers and their patients.